Novel Treatments for Ocular and Periocular Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 84

Special Issue Editor


E-Mail Website
Guest Editor
Ophthalmology Department, Loyola University of Chicago, Chicago, IL, USA
Interests: ocular; ophthalmology

Special Issue Information

Dear Colleagues,

Ocular cancers, though rare, affect patients in all age groups, significantly affecting their vision and survival. Thus, understanding ocular cancers is vital for effective management of the disease. Ocular cancers affect almost every structure of the eye and manifest in various tissues, ranging from intraocular tumors, including retinoblastoma and uveal melanoma, to tumors affecting the ocular surface, such as conjunctival and lacrimal gland carcinomas, as well as orbital tumors. Further, ocular tumors can be primary in nature arising from ocular tissue such as the retinoblastoma or metastasized from distant organs including lymphomas. Given the complexity and diversity of cancers affecting the eye and the stake of losing vision, treating ocular cancers has demanded specialized expertise and advancement in ocular cancer targeted treatments as well as diagnosis. In this Special Issue dedicated to ocular cancers, we request cancer researchers to share their invaluable work to bring together a comprehensive body of research that reflects the current status and advances made in understanding of pathology, detection, diagnosis, and treatment of ocular cancers to benefit both our scientific and non-scientific readers.

Dr. Vidhya R. Rao
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ocular cancer
  • intraocular tumor
  • retinoblastoma
  • uveal melanoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop